<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230805059047N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-23</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effectiveness of herbal product on sexual dysfunction and testosterone levels of men undergoing methadone maintenance treatment</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effectiveness of herbal product on sexual dysfunction and testosterone levels of men undergoing methadone maintenance treatment (MMT)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71831</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment to intervention and control groups
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 60 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 30 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 60, Blinding description: The patient receives the drug (intervention or placebo) in sealed envelopes that are coded. Coding is done by one of the colleagues of the project and the doctor, evaluator and patient are blinded.</study_design>
      <phase>2-3</phase>
      <hc_freetext>sexual dysfunction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Dava al-Basal will be prepared in the form of syrup, a combination of onion extract and honey (along with ginger). The method of making medicine (Dava al-Basal): We heat one liter of white onion juice + 50 grams of dry ginger powder + 2 kg of honey until it reaches a consistency (brix above 80). Since the daily consumption of onion in traditional medicine sources is 6.4 grams, the daily consumption of syrup based on the extract obtained from this amount of plant mass is 20 cc, which will be prescribed to the patient in two divided doses (10 cc every 12 hours).  The most important components of ginger are its essential oil and resins, and control of the final products is done based on total polyphenol. The drug will be prepared in the pharmaceutical laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences. Standardization is based on 20 to 24 mg of total polyphenol (according to gallic acid) is done in every 5 ml of syrup. "Aria Salamat Razi" company, which is approved by the Food and Drug Organization in Iran, will review the microbial tests of herbal product. Intervention 2: Control group:   Placebo (Simple syrup) is based on the British Pharmacopoeia with the addition of permitted edible color B1 of Magnolia Company, which will be consumed in the same way as the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions as well as people working in the industry can apply to receive data.

Conditions:
The data can be used for research purposes.

Where to obtain:
Dr. Gorban Ali Aghighi should be contacted. Email: aliaghighi48@gmail.com

How to obtain:
After contact, information is sent within a few days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ghorbanali Aghighi Alaghejonban</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>First floor, unit 1, No. 179, Omid doctors building, Serah Afsariyeh, 35 meteri Qasr-e-Firuzeh, second 15 meteri of Islamabad, in front of Chehl Seton Hall, Ghoroghi corner</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1786863681</zip>
        <telephone>+98 21 3382 7033</telephone>
        <email>Aliaghighi48@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roshanak Mokaberinejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Traditional Medicine, Faculty of Traditional Medicine, Abbaspur Street (Tavanir), not reaching Vali Asr Street, Shams Dead End</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516745811</zip>
        <telephone>+98 21 8877 3521</telephone>
        <email>rmokaberi@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men (who are recovering from drug addiction) with sexual dysfunction confirmed by a specialist
Age between 20 and 50 years
Not receiving special treatment for sexual dysfunction at least three months before enrolment
Being at the beginning of drug addiction treatment by MMT</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Sexual dysfunction caused by other problems (than addiction)
Using other drugs (started before or during the study)
Alcohol addiction
Severe liver and kidney problems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F11.281</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Opioid dependence with opioid-induced sexual dysfunction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Dava al-Basal will be prepared in the form of syrup, a combination of onion extract and honey (along with ginger). The method of making medicine (Dava al-Basal): We heat one liter of white onion juice + 50 grams of dry ginger powder + 2 kg of honey until it reaches a consistency (brix above 80). Since the daily consumption of onion in traditional medicine sources is 6.4 grams, the daily consumption of syrup based on the extract obtained from this amount of plant mass is 20 cc, which will be prescribed to the patient in two divided doses (10 cc every 12 hours).  The most important components of ginger are its essential oil and resins, and control of the final products is done based on total polyphenol. The drug will be prepared in the pharmaceutical laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences. Standardization is based on 20 to 24 mg of total polyphenol (according to gallic acid) is done in every 5 ml of syrup. "Aria Salamat Razi" company, which is approved by the Food and Drug Organization in Iran, will review the microbial tests of herbal product.</i_keyword>
      <i_keyword>Control group:   Placebo (Simple syrup) is based on the British Pharmacopoeia with the addition of permitted edible color B1 of Magnolia Company, which will be consumed in the same way as the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>International Index of Erectile Function (IIEF) score. Timepoint: At the beginning of the study (before intervention) and 60 days after the start of taking the herbal combination. Method of measurement: International Index of Erectile Function (IIEF).</prim_outcome>
      <prim_outcome>Serum testosterone levels. Timepoint: At the beginning of the study (before intervention) and 60 days after the start of taking the herbal combination. Method of measurement: Testing blood samples to measure testosterone levels using the ELISA method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-02</approval_date>
        <contact_name>Research Ethics Committees of Vice-Chancellor in Research Affairs - Shahid Beheshti University of Me</contact_name>
        <contact_address>Shahid Chamran Highway - Yemen Street - Arabi Street, Shahid Beheshti University of Medical Sciences and Healthcare Services - building number two of the university headquarters - sixth floor Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
